A5069595016- Genetic and Kidney Cyst Diseases
- Renal and related cancers
- Pediatric Urology and Nephrology Studies
- Dialysis and Renal Disease Management
- MRI in cancer diagnosis
- Fetal and Pediatric Neurological Disorders
- Renal cell carcinoma treatment
- Renal Diseases and Glomerulopathies
- HIV-related health complications and treatments
- Chronic Kidney Disease and Diabetes
- Acute Kidney Injury Research
- Chronic Lymphocytic Leukemia Research
- Vitamin C and Antioxidants Research
- Vitamin D Research Studies
- HIV/AIDS drug development and treatment
- Neurological and metabolic disorders
- Eating Disorders and Behaviors
- Venous Thromboembolism Diagnosis and Management
- HIV/AIDS Research and Interventions
- Lipoproteins and Cardiovascular Health
- Antiplatelet Therapy and Cardiovascular Diseases
- Diabetes Treatment and Management
- Genetic Syndromes and Imprinting
- Ovarian cancer diagnosis and treatment
The Rogosin Institute
2019-2024
Cornell University
2019-2024
Weill Cornell Medicine
2019-2024
Merck & Co., Inc., Rahway, NJ, USA (United States)
2023-2024
Icahn School of Medicine at Mount Sinai
2007-2017
University of York
2012
NYU Langone Health
2012
New York University
2008-2010
VA NY Harbor Healthcare System
2010
Columbia University Irving Medical Center
2008
Kidney disease is an important complication of HIV, particularly in minority populations. We describe the burden chronic kidney among 1239 adults followed at urban AIDS center, with estimated prevalence 15.5% (n = 192). Independent predictors included older age, black race, hepatitis C virus exposure, and lower CD4 cell count. These data suggest that remains a common HIV infection era antiretroviral therapy.
This study develops, validates, and deploys deep learning for automated total kidney volume (TKV) measurement (a marker of disease severity) on T2-weighted MRI studies autosomal dominant polycystic (ADPKD). The model was based the U-Net architecture with an EfficientNet encoder, developed using 213 abdominal in 129 patients ADPKD. Patients were randomly divided into 70% training, 15% validation, test sets development. Model performance assessed Dice similarity coefficient (DSC) Bland-Altman...
Overactivation of Src has been linked to the pathogenesis autosomal dominant polycystic kidney disease (ADPKD). This phase 2, multisite study assessed efficacy and safety bosutinib, an oral dual Src/Bcr-Abl tyrosine kinase inhibitor, in patients with ADPKD. Patients ADPKD, eGFR≥60 ml/min per 1.73 m 2 , total volume ≥750 ml were randomized 1:1:1 bosutinib 200 mg/d, 400 or placebo for ≤24 months. The primary endpoint was annualized rate enlargement treated ≥2 weeks who had at least one...
Autosomal dominant polycystic kidney disease (ADPKD) leads to failure in half of those affected. Increased levels adenosine 3':5'-cyclic monophosphate (cAMP) play a critical role progression animal models. Water loading, by suppressing arginine vasopressin (AVP)-stimulated cAMP production, is proposed therapy for ADPKD.The effects acute and sustained water loading on urine osmolality (Uosm) 13 subjects with ADPKD 10 healthy controls were studied. Uosm concentrations measured before after...
Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disorder characterized by the development of multiple cysts in kidneys. It often caused pathogenic mutations PKD1 and PKD2 genes that encode polycystin proteins. Although molecular mechanisms for cystogenesis are not established, concurrent inactivating germline somatic have been previously observed renal tubular epithelium (RTE).To further investigate cellular recessive mechanism RTE, we conducted whole-genome DNA sequencing...
Background Screening for rapidly progressing autosomal dominant polycystic kidney disease (ADPKD) is necessary assigning and monitoring therapies. Height‐adjusted total volume (ht‐TKV) an accepted biomarker clinical prognostication, but represents only a small fraction of information on abdominal MRI. Purpose To investigate the utility other MR features ADPKD to predict progression. Study Type Single‐center retrospective. Population Longitudinal data from 186 subjects with baseline serum...
Abstract Learning Objectives After completing this course, the reader will be able to: Describe need for additional vigilance regarding renal dysfunction when platinums, pegylated liposomal doxorubicin, bevacizumab, and gemcitabine are used prolonged treatment of recurrent ovarian cancer in combination or sequentially following pre-existing damage.Describe quantify risk chronic kidney disease patients treated cancer. CME This article is available continuing medical education credit at...
Total renal volume and changes in kidney are markers of disease progression autosomal-dominant polycystic (ADPKD) but not used clinical practice part because the complexity manual measurements. This study aims to assess intra- interobserver reproducibility a semiautomated volumetric algorithm using fluid-sensitive MRI pulse sequences.Renal volumes 17 patients with ADPKD were segmented from high-resolution coronal HASTE true fast imaging steady-state precession (FISP) MR acquisitions....
Kidney and liver cysts in autosomal dominant polycystic kidney disease (ADPKD) can compress the inferior vena cava (IVC), but IVC compression prevalence its risk factors are unknown.Patients who have ADPKD (n = 216) with abdominal magnetic resonance imaging (MRI) studies age-/sex-matched controls were evaluated for as well azygous vein diameter (a marker of collateral blood flow) aspect ratio (left-to-right dimension divided by anterior-to-posterior a value 1 corresponding to circular (high...
Autosomal dominant polycystic kidney disease (ADPKD), caused by mutations in PKD1 and PKD2 (PKD1/2), has unexplained phenotypic variability likely affected environmental other genetic factors. Approximately 10% of individuals with ADPKD phenotype have no causal mutation detected, possibly due to unrecognized risk variants PKD1/2. This study was designed identify PKD genes through population analyses. We used Wright's F-statistics (Fst) evaluate common single nucleotide (SNVs) potentially...
An estimated 2.5 million patients worldwide were being treated for end-stage kidney disease (ESKD) as of 2016.1 The vast majority with ESKD are hemodialysis (HD ∼89%) and peritoneal dialysis (PD), however patterns HD PD vary internationally.2 Patients on have been observed to be at increased risk major bleeding likely due multiple factors,3 but the epidemiology in different subgroups is not well described. We aimed determine rates overall cause-specific events by key characteristics...
Motivation: By measuring height-adjusted total kidney volume (ht-TKV), renal MRI monitors autosomal dominant polycystic disease (ADPKD) progression and evaluates therapeutic interventions’ efficacy for slowing cyst growth. Goal(s): Since arginine vasopressin (AVP) stimulates growth, reducing with high-water intake (HWI) may slow ADPKD progression. Approach: We test this hypothesis using a case-crossover study 7 subjects, ht-TKV changes on during usual intake. Results: High-water...
Autosomal dominant polycystic kidney disease (ADPKD) eventually leads to end stage renal (ESRD) with an increase in size and number of cysts over time. Progression ESRD has previously been shown correlate total volume (TKV). An accurate relatively simple method perform measurement TKV difficult develop. We propose a semi-automated approach calculating inclusive all ADPKD patients based on b0 images quickly without requiring any calculations or additional MRI Our purpose is evaluate the...